Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tracks safety of bleeding disorder drug OBIZUR

NCT ID NCT06550882

First seen May 20, 2026 · Last updated May 22, 2026 · Updated 1 time

Summary

This study watches how safe OBIZUR is for adults with acquired hemophilia A, a rare condition that causes sudden and severe bleeding. About 9 people will be followed as they receive the drug in regular medical practice. The goal is to track side effects and see how well the drug controls bleeding, but it is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ewha Womans University Medical Center

    RECRUITING

    Seoul, 07804, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kyung Hee University Hospital at Gangdong

    RECRUITING

    Seoul, 05278, South Korea

    Contact Email: •••••@•••••

    Contact

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    RECRUITING

    Seoul, 06591, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ulsan University Hospital

    RECRUITING

    Ulsan, 44033, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.